Table 7.
Targets | Drug | Phase(s) trial | Protocol_IDs* |
---|---|---|---|
BRAF and MEK for the MAPK pathway | Sorafenib and Temsirolimus | I, II | NCT00349206 |
PI3K, AKT and mTOR for the AKT/PI3K pathway | MK2206 plus AZD6244 | I | NCT01021748 |
*Clinical trials selected from http://mmdm.cancercommons.org/ml/index.php/A_Melanoma_Molecular_Disease_Model.